
New FDA warning: The Food and Drug Administration is requiring updated safety labels on all GLP-1 medications because of a possible link to a rare eye condition that can cause permanent vision loss.
Risk is small but serious: An FDA analysis found approximately 6.4 cases of the condition per 100,000 patient-years among GLP-1 users, compared with 3.8 among patients receiving other treatments or a placebo.
Patients should watch for symptoms: Sudden, painless vision loss, blurred vision or blindspots may signal the condition and require immediate medical attention.
Millions of Americans taking popular weight-loss and diabetes medications are being warned about a potentially serious side effect that could threaten their eyesight.
The U.S. Food and Drug Administration announced November 9 that it is requiring new safety warnings on all GLP-1 receptor agonist medications, including Ozempic, Wegovy, Mounjaro and Zepbound, because of evidence suggesting they may increase the risk of a rare eye condition that can cause permanent blindness.
Author: Mark Huffman
Source: Consumer Affairs
Posted: 2026-11-10 12:20:39













